The need of a multicomponent guiding approach to personalize clopidogrel treatment

Patients bearing polymorphisms termed CYP2C19 loss of function (LoF) alleles and ABCB1 -C3435T may do not properly respond to standard dosage of clopidogrel and have an increased risk of thrombosis. Moreover, co-administration of proton pump inhibitors (PPIs) and clopidogrel may attenuate the antipl...

Full description

Saved in:

Bibliographic Details
Published in:	The pharmacogenomics journal 2021-04, Vol.21 (2), p.116-127
Main Authors:	Valeria, Conti, Carmine, Sellitto, Valentina, Manzo, Teresa, Iannaccone, Maria, Costantino, Martina, Torsiello, Giancarlo, Accarino, Giovanna, Nicolella, Graziamaria, Corbi, Amelia, Filippelli
Format:	Article
Language:	English
Subjects:	13/56 38/77 45/22 45/23 631/208/2489/1512 692/700/565 Acute coronary syndromes Animals Antiplatelet therapy Biomedical and Life Sciences Biomedicine Blood Platelets - drug effects Clinical trials Clopidogrel Clopidogrel - therapeutic use Cytochrome P-450 CYP2C19 - genetics Dosage Drug interaction Drug interactions Gene Expression Heart diseases Human Genetics Humans Implants Observational Studies as Topic Oncology Patients Pharmacogenetics Pharmacogenetics - methods Pharmacology, Experimental Pharmacotherapy Precision Medicine - methods Proton pump inhibitors Psychopharmacology Randomized Controlled Trials as Topic Review Article Stents Surgery Therapeutic drug monitoring Thrombosis Vascular surgery
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!